RadNet (RDNT) Stock Price, News & Analysis

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RDNT shares.
View RDNT analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12-month price targets for RadNet's stock. Their RDNT share price targets range from $48.00 to $58.00. On average, they predict the company's share price to reach $53.67 in the next year. This suggests a possible upside of 15.4% from the stock's current price.
View analysts price targets for RDNT or view top-rated stocks among Wall Street analysts.

RadNet's stock was trading at $34.77 at the beginning of the year. Since then, RDNT shares have increased by 33.8% and is now trading at $46.52.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RDNT earnings forecast.

RadNet, Inc. (NASDAQ:RDNT) issued its earnings results on Friday, March, 1st. The medical research company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.11 by $0.09. The medical research company had revenue of $420.38 million for the quarter, compared to analyst estimates of $410.11 million. RadNet had a trailing twelve-month return on equity of 4.72% and a net margin of 0.19%. The business's revenue for the quarter was up 9.5% on a year-over-year basis. During the same period last year, the company posted $0.11 EPS.

ETFs with the largest weight of RadNet (NASDAQ:RDNT) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Services ETF (XHS), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Invesco S&P SmallCap Momentum ETF (XSMO), First Trust Small Cap Growth AlphaDEX Fund (FYC) and SPDR S&P 600 Small Cap Growth ETF (SLYG).iShares U.S. Healthcare Providers ETF (IHF).

RadNet issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion.

174 employees have rated RadNet Chief Executive Officer Howard G. Berger on Glassdoor.com. Howard G. Berger has an approval rating of 45% among the company's employees. This puts Howard G. Berger in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), OPKO Health (OPK), Boeing (BA), Rigel Pharmaceuticals (RIGL), UnitedHealth Group (UNH), Pfizer (PFE) and AT&T (T).

RadNet's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.73%), State of Alaska Department of Revenue (0.06%), Contravisory Investment Management Inc. (0.01%), O ROURKE & COMPANY Inc (0.01%) and Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Christine Nayoma Gordon, David L Swartz, Lawrence L Levitt, Michael N Murdock, Norman R Hames and Ruth Louisa Villigerwilson.
View institutional ownership trends.

Shares of RDNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.